-
Morning Market Gainers
Monday, August 3, 2015 - 9:37am | 199Global-Tech Advanced Innovations Inc. (NASDAQ: GAI) surged 108.33 percent to $6.25 on going private bid of $8.75 per share. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares jumped 33.82 percent to $11.29 as TELESTAR Phase 3 clinical trial met primary endpoint. BiondVax Pharmaceuticals Ltd. -...
-
Benzinga's Top #PreMarket Gainers
Monday, August 3, 2015 - 8:19am | 158Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares climbed 28.55 percent to $10.85 in pre-market trading as TELESTAR Phase 3 clinical trial met primary endpoint. Perion Network Ltd (NASDAQ: PERI) shares rose 11.72 percent to $2.86 in pre-market trading as the company announced better-than-...
-
US Stock Futures Flat Ahead Of Economic Data
Monday, August 3, 2015 - 7:17am | 449Pre-open movers US stock futures traded mostly flat in early pre-market trade. Data on motor vehicle sales will be released today. Data on consumer spending for June will be released at 8:30 a.m. ET, while the manufacturing PMI for July will be released at 9:45 a.m. ET. The ISM manufacturing index...
-
Lexicon Pharmaceuticals Announces Pivotal TELESTAR Phase 3 Clinical Trial Met Primary Endpoint
Monday, August 3, 2015 - 4:25am | 191Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of...
-
Revolade Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder
Friday, July 24, 2015 - 9:02am | 389Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade® (eltrombopag), a Novartis product, for the treatment of adult patients with acquired severe aplastic...
-
Benzinga's Volume Movers
Tuesday, July 7, 2015 - 10:40am | 205Depomed Inc (NASDAQ: DEPO) shares climbed 38 percent to $28.50. The volume of Depomed shares traded was 1871 percent higher than normal. Horizon Pharma PLC (NASDAQ: HZNP) proposed to acquire DepoMed for $29.25 per share in stock. La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged 2.79 percent...
-
Stocks Hitting 52-Week Highs
Monday, July 6, 2015 - 10:21am | 153Catabasis Pharmaceuticals Inc (NASDAQ: CATB) shares climbed 16.49 percent to reach a new 52-week high of $14.44 after the company reported that it has received the FDA Fast Track designation for CAT-1004 for the treatment of Duchenne Muscular Dystrophy. La Jolla Pharmaceutical Company (NASDAQ:...
-
Cantor Boosts Ligand Pharma Target To $93
Friday, June 19, 2015 - 11:07am | 242In a report published Friday, Cantor Fitzgerald analyst Irina Rivkind Koffler maintained a Hold rating on Ligand Pharmaceuticals Inc. (NASDAQ: LGND), while raising the price target from $86 to $93. While the stock appears to be “fairly valued, we are positively biased ahead of the July 26...
-
Metabolix, Inc. Announces $15 Million Equity Private Placement
Tuesday, June 16, 2015 - 8:31am | 209Metabolix, Inc. (Nasdaq: MBLX), an advanced biomaterials company focused on sustainable solutions for the plastics industry, announced today that it has entered into a definitive agreement with Jack W. Schuler, Birchview Capital, Hong Kong Sino-Science Oil & Gas Co., Ltd., certain members of...
-
Benzinga's Top Downgrades
Monday, June 15, 2015 - 10:03am | 242Analysts at FBR Capital downgraded EMC Corporation (NYSE: EMC) from Outperform to Market Perform. The price target for EMC has been lowered from $31.00 to $28.00. EMC shares closed at $27.07 on Friday. Analysts at Deutsche Bank downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) from Buy to Hold...
-
Deutsche Bank Downgrades Ligand Pharmaceuticals To Hold
Monday, June 15, 2015 - 8:10am | 56Analysts at Deutsche Bank downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) from Buy to Hold. Ligand Pharmaceuticals shares have gained 44.75 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. Ligand Pharmaceuticals' shares fell 0.24 percent...
-
FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Friday, June 12, 2015 - 8:01am | 626Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta® (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic immune thrombocytopenia (cITP) who have had an...
-
Morning Market Losers
Tuesday, June 9, 2015 - 9:56am | 324Quiksilver, Inc. (NYSE: ZQK) shares slipped 26.61 percent to $0.910 following Q2 miss and news that management is 'rescinding previously stated financial guidance' for FY15. Christopher & Banks Corporation (NYSE: CBK) shares declined 18.95 percent to $4.32. Christopher & Banks reported a...
-
Benzinga's Top #PreMarket Losers
Tuesday, June 9, 2015 - 8:17am | 189Burlington Stores Inc (NYSE: BURL) shares dropped 7.68 percent to $49.75 in pre-market. Burlington reported in-line earnings for the first quarter, but the company's sales missed analysts' expectations. The company also announced a $200 million stock buyback program. United Natural Foods, Inc...
-
Ligand Acquires Rights to More Than 15 Development Programs from Selexis SA
Monday, May 11, 2015 - 8:16am | 301Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA for $4 million in cash. Highlights of the transaction include the following: The basis for the development...